The mRNA Methylation Program in Leukemia

Principal Investigator:
- Michael Kharas, PhD - Memorial Sloan Kettering Cancer Center

Co-Principal Investigator:
- Samie Jaffrey, MD, PhD - Weill Cornell Medicine

Abstract: Hematopoietic malignancies result from dysregulated self-renewal pathways and an altered differentiation program. Understanding this altered differentiation is essential for identifying novel therapeutic targets in acute myeloid leukemia (AML). Despite the many studies focusing on genetic and epigenetic regulators, it remains unclear if epitranscriptomic regulation is altered in AML and contributes to disease progression. Recent discoveries from our group and others have found that mRNAs are subjected to the base modification N6-methyladenosine (m6A) and this epitranscriptomic regulation is a potent regulator of mRNA stability and protein translation. m6A has emerged as a major regulator of cellular differentiation in studies of embryonic stem cell differentiation. Our preliminary studies suggest that elevated m6A is a hallmark of AML and is required for the blast state that characterizes this cancer. The m6A writer Mettl3 is highly expressed in myeloid leukemia cells and is required for survival. Thus, we will characterize the role of m6A in leukemia by combining the strengths of the Kharas and Jaffrey laboratories. The Kharas laboratory has been studying RNA-binding proteins in normal and malignant hematopoietic self-renewal and the Jaffrey laboratory is one of the world’s experts on RNA methylation. Utilizing technological innovations from the Jaffrey laboratory, we will create a functional nucleotide-level resolution map of m6A in leukemia and mechanistically determine how RNA methylation controls myeloid leukemia cell survival. Our studies will reveal a fundamentally new concept in AML involving aberrant gene regulation through an altered cancer epitranscriptome.